Eburic40 mg

Eburic is a xanthine oxidase inhibitor used for the chronic management of hyperuricemia (high uric acid) in adult patients with gout.

Established / FDA-Approved Use

• Chronic management of hyperuricemia in adult patients with gout who have had an inadequate response to, are intolerant of, or for whom treatment with allopurinol is not medically advisable.

Not Indicated

• Treatment of asymptomatic hyperuricemia (elevated uric acid without gout symptoms).

Important Note on Timing

Eburic is not used to treat an acute gout flare. It is a long-term urate-lowering therapy; starting it can transiently increase the frequency of gout flares due to mobilization of urate crystals from tissue deposits, so flare prophylaxis (e.g. an NSAID or colchicine) is often co-prescribed at initiation.

Guideline-Supported / Off-Label Use

• Prevention of hyperuricemia associated with tumor lysis syndrome in patients undergoing chemotherapy for hematologic malignancies — used in some countries' oncology guidelines and approved in certain international labels; this is not an FDA-approved indication in the United States and should only be used under specialist (oncologist) direction.

Each tablet contains Febuxostat as the active pharmaceutical ingredient, commonly available as 40 mg, 80 mg, and 120 mg film-coated tablets, along with standard pharmaceutical excipients such as binders, fillers, and coating agents.

Eburic is a non-purine selective inhibitor of xanthine oxidase, used orally as a urate-lowering agent in the long-term management of chronic gout. Unlike allopurinol, it is not a purine analog, which allows it to be used in some patients who cannot tolerate allopurinol.

It is supplied as oral film-coated tablets and is intended for once-daily dosing as part of long-term gout management, not for treatment of acute attacks.

Eburic belongs to the therapeutic class of antigout agents, specifically the xanthine oxidase inhibitors (non-purine selective inhibitor class), used as urate-lowering therapy.

Febuxostat works by selectively inhibiting xanthine oxidase, the enzyme responsible for converting hypoxanthine to xanthine and xanthine to uric acid. By blocking this enzyme, Febuxostat reduces the production of uric acid, lowering serum uric acid levels and reducing urate deposition in tissues and joints over time.

Unlike allopurinol, Febuxostat is a non-purine compound, so it does not directly interfere with other purine and pyrimidine synthesis or metabolism pathways at therapeutic doses (though it does inhibit xanthine oxidase-mediated metabolism of certain other drugs — see Drug Interactions).

Febuxostat is metabolized mainly in the liver (via glucuronidation and oxidation) and eliminated through both hepatic and renal pathways, which allows use with only modest dose restriction in mild-to-moderate renal impairment.

Eburic is administered orally, once daily, with or without food. Tablets should be swallowed whole with water. It should be taken consistently at the same time each day to help maintain steady urate-lowering effect. Do not stop or change the dose without consulting a physician, even if symptoms of a gout flare occur after starting treatment.

Contraindicated Interaction

• Azathioprine or Mercaptopurine (6-mercaptopurine): Eburic inhibits xanthine oxidase, the enzyme that metabolizes these drugs. Co-administration can cause dangerous accumulation of azathioprine/mercaptopurine, leading to severe, potentially life-threatening bone marrow suppression. This combination must be avoided (see Contraindications).

Other Notable Interactions

• Theophylline: Xanthine oxidase inhibition may theoretically affect theophylline metabolism; caution and monitoring are advised with concurrent use.
• Didanosine: Xanthine oxidase inhibitors may increase didanosine exposure; concurrent use is generally avoided or requires close monitoring.

No clinically significant interactions have been established with NSAIDs, colchicine, or warfarin at recommended doses. Always inform the physician of all medications being taken, including over-the-counter drugs and supplements.

Common Side Effects

• Liver function test abnormalities
• Nausea
• Joint pain (arthralgia)
• Rash
• Diarrhea
• Headache
• Gout flares (especially during the first weeks of treatment)
• Edema (swelling)

Serious Side Effects (Seek Medical Attention)

• Signs of liver injury: yellowing of the skin/eyes (jaundice), dark urine, unusual fatigue, right upper abdominal pain (rare cases of hepatic failure, some fatal, have been reported).
• Serious hypersensitivity/skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms (DRESS) — symptoms may include widespread rash, blistering, fever, or swollen lymph nodes.
• Symptoms of a heart attack or stroke, such as chest pain, shortness of breath, weakness on one side of the body, or slurred speech (see Precautions and Warnings for cardiovascular risk).

Pregnancy: Data on the use of Eburic in pregnant women are limited. Animal studies have not shown adverse fetal effects at doses well above the human dose, but this does not guarantee human safety. Eburic should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Eburic passes into human breast milk (it has been detected in the milk of lactating animals). Because of the potential for adverse effects in a breastfeeding infant, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother, in consultation with a physician.

Boxed Warning: Cardiovascular Risk

Gout patients with pre-existing major cardiovascular disease treated with Eburic had a higher rate of cardiovascular death compared with those treated with allopurinol in a large cardiovascular outcomes trial (CARES). Eburic should generally be reserved for patients who have had an inadequate response, intolerance, or contraindication to allopurinol. Discuss the risks and benefits, including cardiovascular risk factors, with a physician before starting therapy, and seek prompt medical attention for chest pain, shortness of breath, or other signs of a heart attack or stroke.

Increased Gout Flares at Initiation

Starting Eburic may increase gout flares initially due to mobilization of urate from tissue deposits. Do not discontinue therapy solely because of a flare; flare prophylaxis is often used during the first months of treatment as directed by a physician.

Hepatic Effects

Liver function abnormalities have been reported, and rare cases of hepatic failure (some fatal) have occurred. Liver function testing is recommended before starting and periodically during treatment. Discontinue and seek medical attention if signs of liver injury appear.

Serious Hypersensitivity Reactions

Rare but serious skin/hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS) have been reported, generally within the first month of treatment. Discontinue immediately and seek medical care if a serious skin reaction or hypersensitivity is suspected.

Organ Transplant Recipients

Eburic has not been adequately studied in organ transplant recipients and is not recommended in this population unless specifically advised by a physician, partly due to the interaction risk with azathioprine (see Contraindications).

Limited data are available on overdose with Eburic; doses up to several times the usual maximum have been tolerated without specific dose-limiting toxicity in studies, but overdose should still be treated seriously. If an overdose is suspected, seek immediate medical attention or contact a poison control center / emergency services right away. Treatment of overdose is supportive and symptomatic, based on the patient's clinical condition, and should only be managed by medical professionals.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Eburic have not been established in patients under 18 years of age; it is not recommended for pediatric use.

Elderly (Geriatric Use)

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients, but caution is advised given the higher likelihood of decreased hepatic, renal, or cardiac function and concomitant disease or other drug therapy in this age group.

Renal Impairment

No dosage adjustment is needed for mild-to-moderate renal impairment. Data are limited in severe renal impairment (CrCl 15–29 mL/min); use with caution and typically limit to the lower (40 mg) dose under physician guidance.

Hepatic Impairment

No dosage adjustment is needed for mild-to-moderate hepatic impairment. Not well studied in severe hepatic impairment; use with caution.

Eburic is a long-term, ongoing therapy for chronic gout management rather than a short-course treatment. It is typically continued indefinitely to keep serum uric acid below target levels and prevent future gout flares and tophi formation, with periodic monitoring of uric acid and liver function as directed by a physician. Treatment duration should be individualized and reviewed regularly by the prescribing physician.

Antigout agent; Xanthine oxidase inhibitor (non-purine selective inhibitor).

Febuxostat selectively and potently inhibits xanthine oxidase in both its oxidized and reduced forms, blocking the conversion of hypoxanthine to xanthine and xanthine to uric acid. This reduces serum uric acid production, allowing gradual dissolution of urate crystal deposits and prevention of new crystal formation, thereby reducing the frequency of gout flares over time.

C

The safety and efficacy of Eburic have not been established in pediatric patients (under 18 years of age). It is therefore not recommended for use in children or adolescents outside of specialist clinical judgement in rare, specific circumstances (e.g. certain pediatric hematology/oncology settings for tumor lysis syndrome prevention, only under specialist direction). Routine use in the pediatric population for gout is not supported by current data.